ARTICLE | Product Development
Gilead’s $5.1B Galapagos deal threads the needle between M&A and licensing
How Gilead structured its 10-year tie-up with Galapagos to prevent the brain drain that follows acquisitions
July 19, 2019 10:01 PM UTC
The structure of Gilead’s partnership with Galapagos gives the U.S. biotech access to all of Galapagos’ programs, without the brain drain that followed its acquisition of Kite.
Human capital was the driver behind Gilead Sciences Inc.’s decision to stop short of acquiring the inflammation and fibrosis company, and instead enter a 10-year option agreement covering nearly all of Galapagos N.V.’s current and future pipeline programs. ...